Gyre Therapeutics Inc. (GYRE)
NASDAQ: GYREHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 7.04 0.00%
GYRE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $746.48M
- Forward P/E
- 117.33
- EPS (TTM)
- -$0.25
- Dividend yield
- None
- Ex-dividend date
- Jan 13, 2023
- 52-week range
- 5.44 – 9.42
- Day range
- 6.76 – 7.09
- Volume / Avg
- 76.63K / 105.93K
- Beta
- —
- Shares outstanding
- 106.03M
- Next earnings
- Nov 6, 2026
52-week range
GYRE stock today
Gyre Therapeutics (GYRE) closed at $7.04 on Oct 9, up 4.14% (+$0.28), versus the S&P 500's 0.59% gain. Shares are 25.3% below their 52-week high of $9.42, set on Oct 16, 2025 and 29.4% above the 52-week low of $5.44, in the middle of the past year's range. GYRE is down 0.3% year to date, underperforming the S&P 500 (+14.2%). Over the past 12 months, the stock has lost 1.5%.
Gyre Therapeutics has posted a net loss over the last twelve months (EPS of -$0.25), so its P/E ratio is not meaningful. Gyre Therapeutics's next earnings report is expected on Nov 6, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Gyre Therapeutics
Company profileGyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Ying Luo Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 625
- IPO year
- 2006
- Website
- gyretx.com
Analyst forecast
ForecastConsensus (3 analysts)
none
Avg. price target
$18.67+165.20%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 6, 2026
- EPS estimate
- $-0.14
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $3.60
- Ex-dividend date
- Jan 13, 2023
Gyre Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| VSTMVerastem Inc. | 8.38 | +3.33% | $758.92M | vs GYRE |
| LXRXLexicon Pharmaceuticals Inc. | 1.68 | -4.55% | $747.53M | vs GYRE |
| IVAInventiva S.A. American Depository Shares | 3.16 | -4.82% | $746.46M | vs GYRE |
| ANNXAnnexon Inc. | 4.02 | +0.50% | $762.11M | vs GYRE |
| APMDApnimed Inc. | 18.52 | +1.65% | $771.00M | vs GYRE |
| AVTXAvalo Therapeutics Inc. | 13.65 | +1.64% | $732.05M | vs GYRE |
| DSGNDesign Therapeutics Inc. | 11.65 | +1.39% | $729.08M | vs GYRE |
| IMMXImmix Biopharma Inc. | 9.46 | +1.83% | $784.26M | vs GYRE |
Indexes, lists and sector
Gyre Therapeutics stock FAQ
What is Gyre Therapeutics's stock price today?
GYRE last traded at $7.04 as of Oct 9, 4:00 PM EDT, up 4.14% on the day. Prices are delayed at least 15 minutes.
Does Gyre Therapeutics pay a dividend?
Yes. Gyre Therapeutics pays $0.00 per share annually. The most recent dividend of $3.60 had an ex-dividend date of Jan 13, 2023.
When is Gyre Therapeutics's next earnings date?
Gyre Therapeutics is expected to report earnings on Friday, November 6, 2026. Analysts expect EPS of $-0.14.
Who is Gyre Therapeutics's CEO?
Dr. Ying Luo Ph.D. is the chief executive officer of Gyre Therapeutics Inc., which has about 625 employees.
Has GYRE ever split its stock?
Yes. The most recent GYRE stock split was a 1-for-15 split on Oct 31, 2023, one of 3 splits on record.
What is the GYRE 52-week high?
The 52-week high for GYRE is $9.42 and the 52-week low is $5.44. The stock is currently 25.3% below its high.